Akt Cancer Research Results

Akt, PKB-Protein kinase B: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport.

Inhibitors:
-Curcumin: downregulate AKT phosphorylation and signaling.
-Resveratrol
-Quercetin: inhibit the PI3K/AKT pathway.
-Epigallocatechin Gallate (EGCG)
-Luteolin and Apigenin: inhibit AKT phosphorylation


Stroke, Cerebral Ischemic Stroke: Click to Expand ⟱
Ischemic stroke is also called brain ischemia and cerebral ischemia. Ischemia is the medical term for "lack of blood supply."

Quick Reference

Mechanism Top Compounds
Blood flow / anti-thrombotic support Aspirin, Ginkgo biloba, Panax notoginseng, Salvia miltiorrhiza
Membrane repair / cholinergic support Citicoline, Alpha-GPC
Antioxidant / ROS control EGCG, Curcumin, Quercetin, Tocotrienols
Anti-inflammatory / NF-κB / cytokines Curcumin, Luteolin, Baicalin
Mitochondrial protection Resveratrol, Citicoline
BBB protection Rosmarinic acid, Astragaloside IV

Stroke/Product Table - Dose + Practical Therapeutic Index

Compound Class Primary Mechanisms Key Stroke Effects Evidence Level Phase Utility Human Dose Range Approx. HED mg/kg/day Practical Therapeutic Index
Aspirin NSAID / anti-platelet COX-1 inhibition; ↓ thromboxane A2; ↓ platelet aggregation Reduces recurrent ischemic stroke risk Strong clinical; standard of care Acute + prevention 81–325 mg/day ~1.2–4.6 mg/kg/day for 70 kg adult High, but bleeding-risk limited
Citicoline / CDP-choline Choline donor Membrane repair; ↑ phosphatidylcholine; ↓ free fatty acid release May support neurological and cognitive recovery Clinical; mixed acute results, better recovery/cognition signal Recovery 500–2000 mg/day ~7–29 mg/kg/day for 70 kg adult Moderate–High
Alpha-GPC Choline donor ↑ acetylcholine; phospholipid support May support post-stroke cognition Clinical; moderate support Recovery 300–1200 mg/day ~4–17 mg/kg/day for 70 kg adult Moderate; TMAO concern
Ginkgo biloba Herbal extract Cerebral blood flow; antioxidant; anti-platelet May support perfusion and cognition Clinical + preclinical Recovery 120–240 mg/day standardized extract ~1.7–3.4 mg/kg/day Moderate; bleeding interaction caution
Panax notoginseng / PNS Saponins Anti-thrombotic; perfusion; anti-inflammatory Improved blood flow/recovery measures in some studies Clinical mainly China + preclinical Acute + recovery Variable extract-dependent Study-specific; often preclinical HED needed Moderate; bleeding interaction caution
Salvia miltiorrhiza / Danshen Herbal extract Microcirculation; vascular protection; anti-platelet May support vascular recovery Clinical mainly China + preclinical Acute + recovery Variable extract/root equivalent Study-specific Moderate; bleeding interaction caution
Baicalin Flavonoid Anti-inflammatory; anti-apoptotic; antioxidant Neuroprotection in ischemic injury models Preclinical + limited clinical Acute No established stroke dose Preclinical HED only Moderate–Low
Curcumin Polyphenol ↓ NF-κB; ↓ cytokines; antioxidant Reduced infarct size/inflammation in models Strong preclinical Acute + recovery 500–2000 mg/day bioavailable form ~7–29 mg/kg/day Moderate; bioavailability limited
Resveratrol Polyphenol SIRT1; mitochondrial protection; anti-apoptotic Reduced apoptosis/infarct injury in models Strong preclinical Acute + recovery 100–500 mg/day ~1.4–7.1 mg/kg/day Moderate; bioavailability limited
EGCG Catechin ROS scavenging; vascular protection Reduced neuronal injury in models Strong preclinical Acute 200–400 mg/day EGCG ~2.9–5.7 mg/kg/day Moderate; liver-dose caution
Quercetin Flavonoid Antioxidant; anti-inflammatory; anti-edema Reduced edema/infarct size in models Strong preclinical Acute 500–1000 mg/day ~7–14 mg/kg/day Moderate
Melatonin Indoleamine Mitochondrial antioxidant; anti-inflammatory Reduced ischemia-reperfusion injury in models Preclinical + limited clinical interest Acute + recovery 3–10 mg/day ~0.04–0.14 mg/kg/day Moderate–High
Tocotrienols Vitamin E subtype Lipid antioxidant; membrane protection Neuroprotection in ischemic models Preclinical + limited clinical Acute 100–300 mg/day ~1.4–4.3 mg/kg/day Moderate
Luteolin Flavonoid NF-κB / Nrf2 / PI3K-Akt modulation Reduced inflammation/neuroprotection in models Strong preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Ferulic acid Phenolic acid Antioxidant; vasodilation; vascular protection Improved blood flow/reduced injury in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Rosmarinic acid Phenolic acid BBB protection; antioxidant; anti-inflammatory Reduced BBB disruption in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Berberine Alkaloid AMPK activation; metabolic/vascular protection Neuroprotection in ischemia models Preclinical Prevention + recovery 500–1500 mg/day ~7–21 mg/kg/day Moderate; interaction caution
Huperzine A Alkaloid AChE inhibition; cholinergic support May support cognitive recovery Preclinical + cognitive clinical context Recovery 100–200 µg/day ~0.001–0.003 mg/kg/day Low–Moderate; narrow cholinergic tolerance
Honokiol Lignan Mitochondrial protection; anti-inflammatory Reduced ischemic neuronal injury in models Preclinical Acute + recovery No established stroke dose Preclinical HED only Low
HED: Human Equilvalent Dose
Scientific Papers found: Click to Expand⟱
4276- BA,    Baicalin Attenuates Oxygen–Glucose Deprivation/Reoxygenation–Induced Injury by Modulating the BDNF-TrkB/PI3K/Akt and MAPK/Erk1/2 Signaling Axes in Neuron–Astrocyte Cocultures
- in-vivo, Stroke, NA
*BDNF↑, *neuroP↑, *TrkB↑, *PI3K↑, *Akt↑, *MAPK↑, *ERK↑, *NO↓, *MDA↓, *SOD↑, *TNF-α↓, *IL1β↓, *IL6?,
2480- Ba,    Inhibition of 12/15 lipoxygenase by baicalein reduces myocardial ischemia/reperfusion injury via modulation of multiple signaling pathways
- in-vivo, Stroke, NA
*12LOX↓, *ROS↓, *ERK↑, *Akt↑, *p38↓, *JNK↓, *NF-kB↓, *cardioP↑,
5768- CAPE,    Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*antiOx↑, *Inflam↑, *AntiCan↑, *NRF2↑, *GSK‐3β↑, *Akt↑, *PI3K↑, *ROS↓, *SOD↑, *GSH↑, *MDA↓, *tau↓, *neuroP↑, *memory↑, *AChE↓, *other↝, *lipid-P↓,
194- MF,    Electromagnetic Field as a Treatment for Cerebral Ischemic Stroke
- Review, Stroke, NA
*BAD↓, *BAX↓, *Casp3↓, *Bcl-xL↑, *p‑Akt↑, *MMP9↓, *p‑ERK↑, *HIF-1↓, *ROS↓, *VEGF↑, *Ca+2↓, *SOD↑, *IL2↑, *p38↑, *HSP70/HSPA5↑, *Apoptosis↓, *ROS↓, *NO↓,
98- QC,    Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway
- in-vivo, Stroke, NA
*Bcl-2↑, *BAX↓, *Bax:Bcl2↓, *cardioP↑, *Akt↑, *PI3K↑, *LDH↓,
4162- QC,    Quercetin attenuates cell apoptosis in focal cerebral ischemia rat brain via activation of BDNF-TrkB-PI3K/Akt signaling pathway
- in-vivo, Stroke, NA
*neuroP↑, *BDNF↑, *TrkB↑, *p‑Akt↑,
3341- QC,    Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application
- Review, Var, NA - Review, Stroke, NA
*antiOx↑, *BioAv↑, *GSH↑, *AChE↓, *BChE↓, *H2O2↓, *lipid-P↓, *SOD↑, *SOD2↑, *Catalase↑, *GPx↑, *neuroP↑, *HO-1↑, *cardioP↑, *MDA↓, *NF-kB↓, *IKKα↓, *ROS↓, *PI3K↑, *Akt↑, *hepatoP↑, P53↑, BAX↑, IGF-1R↓, Akt↓, AR↓, TumCP↓, GSH↑, SOD↑, Catalase↑, lipid-P↓, *TNF-α↓, *Ca+2↓,
3338- QC,    Quercetin: Its Antioxidant Mechanism, Antibacterial Properties and Potential Application in Prevention and Control of Toxipathy
- Review, Var, NA - Review, Stroke, NA
*antiOx↑, *GSH↑, *ROS↓, *Dose↑, *NADPH↓, *AMP↓, *NF-kB↓, *p38↑, *MAPK↑, *SOD↑, *MDA↓, *iNOS↓, *Catalase↑, *PI3K↑, *Akt↑, *lipid-P↓, *memory↑, *radioP↑, *neuroP↑, *MDA↓,
3049- SK,    Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
- in-vivo, Nor, NA - NA, Stroke, NA
*neuroP↑, *p‑PTEN↓, *p‑Akt↑, *Bcl-2↑, *BAX↓, *cognitive↑, *BDNF↑,

Showing Research Papers: 1 to 9 of 9

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 9

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↑, 1,   GSH↑, 1,   lipid-P↓, 1,   SOD↑, 1,  

Cell Death ⓘ

Akt↓, 1,   BAX↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1R↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 3,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 3,   MDA↓, 5,   NRF2↑, 1,   ROS↓, 6,   SOD↑, 5,   SOD2↑, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   AMP↓, 1,   LDH↓, 1,   NADPH↓, 1,  

Cell Death ⓘ

Akt↑, 6,   p‑Akt↑, 3,   Apoptosis↓, 1,   BAD↓, 1,   BAX↓, 3,   Bax:Bcl2↓, 1,   Bcl-2↑, 2,   Bcl-xL↑, 1,   Casp3↓, 1,   iNOS↓, 1,   JNK↓, 1,   MAPK↑, 2,   p38↓, 1,   p38↑, 2,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 2,   p‑ERK↑, 1,   GSK‐3β↑, 1,   PI3K↑, 5,   p‑PTEN↓, 1,  

Migration ⓘ

Ca+2↓, 2,   MMP9↓, 1,  

Angiogenesis & Vasculature ⓘ

HIF-1↓, 1,   NO↓, 2,   VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

IKKα↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6?, 1,   Inflam↑, 1,   NF-kB↓, 3,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BChE↓, 1,   BDNF↑, 3,   tau↓, 1,   TrkB↑, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   Dose↑, 1,  

Clinical Biomarkers ⓘ

IL6?, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 3,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 2,   neuroP↑, 6,   radioP↑, 1,  
Total Targets: 65

Scientific Paper Hit Count for: Akt, PKB-Protein kinase B
4 Quercetin
1 Baicalin
1 Baicalein
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Magnetic Fields
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:36  Cells:%  prod#:%  Target#:4  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page